What short-course ceftriaxone regimens are recommended?

Short-Course Ceftriaxone Regimens

For uncomplicated gonorrhea, ceftriaxone 125 mg IM as a single dose is the established short-course regimen, with extensive evidence demonstrating 98-99% cure rates. 1, 2, 3

Gonococcal Infections (Single-Dose Regimens)

Uncomplicated Urogenital, Anorectal, and Cervical Infections

• Ceftriaxone 125 mg IM single dose is the primary short-course regimen 1, 4, 2
  • Provides sustained bactericidal blood levels
  • Cures 98.9-99.1% of uncomplicated infections
  • Must be combined with treatment for presumptive Chlamydia coinfection (azithromycin 1 g single dose or doxycycline 100 mg BID × 7 days)

Pharyngeal Gonorrhea

• Ceftriaxone 125 mg IM single dose 1, 4
  • Pharyngeal infections are more difficult to eradicate (>90% cure threshold)
  • This is one of the few regimens reliably effective for pharyngeal sites
  • Alternative: Ciprofloxacin 500 mg PO single dose (where quinolone resistance is not prevalent)

Gonococcal Conjunctivitis

• Ceftriaxone 1 g IM single dose 4, 5
  • Plus saline lavage of infected eye
  • Higher dose required for ocular infection

Non-Gonococcal Short-Course Regimens

Uncomplicated Cystitis (Recent Evidence)

• 3 days total of IV/PO beta-lactam therapy 6
  • Recent 2025 study showed non-inferiority of ≤3 days versus ≥4 days
  • Ceftriaxone was most commonly used agent
  • Transition to oral therapy recommended when feasible
  • 15.2% failure rate comparable to longer courses (15.8%)

Acute Pyelonephritis in Women

• 1 g ceftriaxone IV/IM day 1, then cefixime 400 mg PO daily × 6 days (7 days total) 7
  • 2016 study showed 100% bacteriological cure on day 9
  • All patients apyrexial within 2 days
  • No recurrences at day 37 follow-up
  • This challenges traditional 10-14 day recommendations

Leptospirosis

• Ceftriaxone 1-2 g daily × 3-6 days 8
  • Retrospective data from 21 patients (both uncomplicated and severe forms)
  • Apyrexia within 2 days in all patients
  • No relapses observed
  • Applies to patients responding quickly to therapy

Community-Acquired Pneumonia

• Ceftriaxone 3-7 days (versus traditional 7-10 days) 9
  • Meta-analysis of 7 RCTs (5,438 patients) showed no difference in:
    • Clinical success (OR 0.89; 95% CI 0.74-1.07)
    • Mortality (OR 0.57; 95% CI 0.23-1.43)
    • Adverse events (OR 0.90; 95% CI 0.72-1.13)
  • Applies to mild-to-moderate severity CAP in adults and children

Pediatric Short-Course Considerations

Acute Otitis Media

• Ceftriaxone 50 mg/kg IM single dose (max 1 gram) 3

Pediatric Pneumonia

• 5-7 days versus 7-14 days 10
  • 2026 RCT showed comparable overall efficacy
  • Short course reduced hospital stay and adverse events
  • Standard course had lower recurrence rates
  • Clinical Algorithm: Use short course for mild cases with prompt inflammatory response; use standard course for severe cases or delayed inflammation resolution

Critical Caveats

Resistance Considerations

• Quinolone alternatives (ciprofloxacin, ofloxacin) should not be used for:
  • Men who have sex with men
  • Infections acquired in California, Hawaii, or internationally
  • Areas with elevated quinolone-resistant N. gonorrhoeae prevalence 2

Neonatal Dosing

• IV doses must be given over 60 minutes (not 30 minutes) to reduce bilirubin encephalopathy risk 3
• Contraindicated in premature neonates and those requiring calcium-containing IV solutions

Treatment Failure Management

• For suspected ceftriaxone failure in gonorrhea: gentamicin 240 mg IM + azithromycin 2 g PO (single doses) 11
• Culture and susceptibility testing mandatory
• Report to public health within 24 hours

Calcium Interaction Warning

• Never mix ceftriaxone with calcium-containing solutions (Ringer's, Hartmann's) due to precipitation risk 3
• In non-neonates, may give sequentially if lines thoroughly flushed

Duration Principles

The FDA label specifies that ceftriaxone therapy should generally continue at least 2 days after signs and symptoms resolve, with usual duration 4-14 days for most infections 3. However, the single-dose regimens for uncomplicated gonorrhea represent the most robust short-course evidence, with decades of clinical validation showing no need for extended therapy when appropriate single doses are used.